Long-term survival of kidneys transplanted from live A2 donors to O and B recipients

Am J Transplant. 2007 May;7(5):1181-4. doi: 10.1111/j.1600-6143.2007.01750.x. Epub 2007 Mar 12.

Abstract

The long-term outcome of kidneys transplanted from blood group A(2) live donors into blood group O or B candidates is not known. From 1986 through 2006, we transplanted eight blood group O patients and one blood group B patient with kidneys from blood group A(2) live donors. Immunosuppression was no different for these patients than for ABO-compatible recipients. All patients received methylprednisolone, cyclosporine or tacrolimus and azathioprine or mycophenolate mofetil with or without antibody induction (monoclonal or polyclonal). Of the nine live-donor A(2) to O and B transplants performed, seven grafts remain functioning. One of those seven was lost to follow-up at 9.2 years with a functioning kidney. Of the remaining six patients, length of follow-up is 10.4, 6.5, 5.3, 4, 2.1 and 1 years. Of the two patients who lost their grafts, one died with a functioning graft (DWFG) at 8.8 years and one lost his graft at 13.2 years due to noncompliance with immunosuppression. These data show that good long-term graft survival can be expected in live-donor A(2) to O and B transplantation despite some of those patients experiencing the type of clinical problems seen with ABO-compatible transplants.

MeSH terms

  • ABO Blood-Group System / immunology*
  • Azathioprine / therapeutic use
  • Blood Grouping and Crossmatching
  • Cyclosporine / therapeutic use
  • Follow-Up Studies
  • Graft Rejection / immunology
  • Graft Rejection / prevention & control
  • Graft Survival / immunology
  • Graft Survival / physiology*
  • Humans
  • Immunosuppression Therapy / methods
  • Immunosuppressive Agents / therapeutic use
  • Kidney Transplantation / immunology*
  • Kidney Transplantation / methods
  • Kidney Transplantation / physiology*
  • Living Donors*
  • Methylprednisolone / therapeutic use
  • Mycophenolic Acid / analogs & derivatives
  • Mycophenolic Acid / therapeutic use
  • Tacrolimus / therapeutic use
  • Time Factors
  • Treatment Outcome

Substances

  • ABO Blood-Group System
  • Immunosuppressive Agents
  • Cyclosporine
  • Mycophenolic Acid
  • Azathioprine
  • Tacrolimus
  • Methylprednisolone